Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Highlights Advancements of Akston Biosciences' Ambifect® Fc-fusion Platform

Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Overview Company: Akston Biosciences Indication: SARS-CoV-2 Vaccination Drug: AKS-452 Trial Phase: Phase 2 NCT ID: N/A Study Results Akston Biosciences has published the results of their Phase II clinical trial for the AKS-452 vaccine in Nature Vaccines. This study, conducted in the Netherlands, aimed to boost the immune re..